rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2009-5-3-83-88rpcardio-669Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯANGIOTENSIN CONVERTING ENZYME INHIBITORS IN MANAGEMENT OF PATIENTS WITH CHRONIC HEART FAILUREПОЗИЦИИ ИНГИБИТОРОВ АНГИОТЕНЗИНПРЕВРАЩАЮЩЕГО ФЕРМЕНТА В ТЕРАПИИ БОЛЬНЫХ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮТерещенкоС. Н.TereshchenkoS. N.

121552, Москва, ул. 3-я Черепковская, д.15а

127473, Москва, ул. Делегатская, д.20/1

ul. Tretya Cherepkovskaya 15a, 121552 Moscow

ul. Delegatskaya 20/1, 127473 Moscow

ДжаианиН. А.DzhaianiN. A.

121552, Москва, ул. 3-я Черепковская, д.15а

127473, Москва, ул. Делегатская, д.20/1

ul. Tretya Cherepkovskaya 15a, 121552 Moscow

ul. Delegatskaya 20/1, 127473 Moscow

doctornj@yandex.ruРоссийский кардиологический научно-производственный комплекс, Московский государственный медико-стоматологический университетРоссияRussian Cardiology Research and Production Complex, Moscow State University of Medicine and DentistryRussian Federation200910012016538388Copyright © Tereshchenko S.N., Dzhaiani N.A., 20162016Терещенко С.Н., Джаиани Н.А.Tereshchenko S.N., Dzhaiani N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/669

The role of ACE inhibitors in modern pharmacotherapy of patients with chronic heart failure (CHF) is discussed. The actual usage of these highly effective drugs is underlined taking into account high prevalence and social significance of CHF. Necessity of ACE inhibitors usage is confirmed by pharmacodynamic features of these drugs in CHF. The special attention is given to enalapril, that has the biggest evidence base in treatment of CHF patients.

Освещается роль ингибиторов АПФ в современной фармакотерапии больных хронической сердечной недостаточностью (ХСН). Подчеркивается возросшая актуальность применения этой группы высокоэффективных при ХСН препаратов с учетом высокой распространенности и социальной значимости заболевания. Необходимость применения ингибиторов АПФ подкрепляется фармакодинамическими особенностями этих препаратов при ХСН. Особое место уделено эналаприлу как препарату с самой большой доказательной базой применения в лечении больных ХСН.

ингибиторы АПФхроническая сердечная недостаточностьэналаприлACE inhibitorschronic heart failureenalaprilReferencesMcMurray J.J., Stewart J. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83(5):596-602.McMurray J.J., Stewart J. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83(5):596-602.Paulus W.J., Tschöpe C., Sanderson J.E. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28(20):2539-50.Paulus W.J., Tschöpe C., Sanderson J.E. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28(20):2539-50.Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Даниелян М.О. Первые результаты национального эпидемиологического исследования – эпидемиологическое обследование больных ХСН в реальной клинической практике – (ЭПОХА-О-ХСН). Журнал Сердечная недостаточность 2003;4(3):116-21.Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Даниелян М.О. Первые результаты национального эпидемиологического исследования – эпидемиологическое обследование больных ХСН в реальной клинической практике – (ЭПОХА-О-ХСН). Журнал Сердечная недостаточность 2003;4(3):116-21.Терещенко С.Н., Джаиани Н.А., Жиров И.В., Ускач Т.М. Хроническая сердечная недостаточность. Вопросы диагностики и лечения. М.: Анахарсис; 2006.Терещенко С.Н., Джаиани Н.А., Жиров И.В., Ускач Т.М. Хроническая сердечная недостаточность. Вопросы диагностики и лечения. М.: Анахарсис; 2006.Braunwald E. ACE inhibitors — a cornerstone of treatment of heart failure. New Engl J Med 1991;325(5):351-3.Braunwald E. ACE inhibitors — a cornerstone of treatment of heart failure. New Engl J Med 1991;325(5):351-3.Garg R., Yusuf S. Overview of randomized trials of ACE Inhibitors on mortality and morbidity in pts with heart failure. JAMA 1995;273(18): 1450- 6.Garg R., Yusuf S. Overview of randomized trials of ACE Inhibitors on mortality and morbidity in pts with heart failure. JAMA 1995;273(18): 1450- 6.Hunt S.A., Baker D.W., Chin M.H. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38(7):2101-13.Hunt S.A., Baker D.W., Chin M.H. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38(7):2101-13.Pfeffer M.A. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993; 18 Suppl 1:430-5.Pfeffer M.A. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 1993; 18 Suppl 1:430-5.SOLVD Investigators. Effect of enalapril on survival in patients with rediced left ventricular ejection fractions and congestive heart gfailure. N Engl J Med 1991;325(5):293-302.SOLVD Investigators. Effect of enalapril on survival in patients with rediced left ventricular ejection fractions and congestive heart gfailure. N Engl J Med 1991;325(5):293-302.Kober L., Torp-Pedersen C., et al. A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-6.Kober L., Torp-Pedersen C., et al. A clinical trial of the angiotensin-convertingenzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-6.Никифоров В.С., Свистов А.С. Современные направления применения ингибиторов ангиотензин-превращающего фермента в клинической практике. ФАРМиндекс ПРАКТИК 2005;(7):21-31.Никифоров В.С., Свистов А.С. Современные направления применения ингибиторов ангиотензин-превращающего фермента в клинической практике. ФАРМиндекс ПРАКТИК 2005;(7):21-31.Cohn J.N., Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325(5):303–10.Cohn J.N., Johnson G., Ziesche S. et al. A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325(5):303–10.Pfeffer M., Braunwald E., Moye L. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327(10): 669–77.Pfeffer M., Braunwald E., Moye L. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327(10): 669–77.Sigurdsson A., Swedberg K. Neurohormonal activation and congestive heart failure: Today’s experience with ACE inhibitors and rationale for their use. Eur Heart J 1995;16 Suppl N:65-72.Sigurdsson A., Swedberg K. Neurohormonal activation and congestive heart failure: Today’s experience with ACE inhibitors and rationale for their use. Eur Heart J 1995;16 Suppl N:65-72.DiBianco R. ACE inhibitirs in the treatment of heart failure. Clin Cardiol 1990;13(6 Suppl 7):VII32-8.DiBianco R. ACE inhibitirs in the treatment of heart failure. Clin Cardiol 1990;13(6 Suppl 7):VII32-8.Fujii M., Wada A., Ohnishi M., et al. Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. J Cardiovasc Pharmacol 2004;44 Suppl 1:S346–9.Fujii M., Wada A., Ohnishi M., et al. Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. J Cardiovasc Pharmacol 2004;44 Suppl 1:S346–9.Мареев В.Ю. Основные достижения в области понимания, диагностики и лечения ХСН в 2003 году. Журнал Сердечная недостаточность 2004;(1):16–21.Мареев В.Ю. Основные достижения в области понимания, диагностики и лечения ХСН в 2003 году. Журнал Сердечная недостаточность 2004;(1):16–21.Jorde U.P., Vittorio T.J., Dimayuga C.A., et al. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Am J Cardiol 2004;94(12):1501– 5.Jorde U.P., Vittorio T.J., Dimayuga C.A., et al. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure. Am J Cardiol 2004;94(12):1501– 5.The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10):685–91.The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10):685–91.McKelvie R.S., Rouleau J.L., White M. et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003;24(19):1727–34.McKelvie R.S., Rouleau J.L., White M. et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003;24(19):1727–34.The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429– 35.The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316(23):1429– 35.Swedberg K., Kjekshus J., Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136–9.Swedberg K., Kjekshus J., Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136–9.Jong P., Yusuf S., Rousseau M.F. et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361(9372):1843–8.Jong P., Yusuf S., Rousseau M.F. et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361(9372):1843–8.Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low doses and high doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure: ATLAS study group. Circulation 1999;100(23):2312–8.Packer M., Poole-Wilson P.A., Armstrong P.W. et al. Comparative effects of low doses and high doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure: ATLAS study group. Circulation 1999;100(23):2312–8.Shindler D.M., Kostis J.B., Yusuf S. et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77(11):1017–20.Shindler D.M., Kostis J.B., Yusuf S. et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77(11):1017–20.Bourassa M.G., Gurn O., Bangdiwala S.I. et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22(4 suppl A):14A– 19A.Bourassa M.G., Gurn O., Bangdiwala S.I. et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol 1993;22(4 suppl A):14A– 19A.Willenheimer R., van Veldhuisen D.J., Silke B. et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112(16):2426–35.Willenheimer R., van Veldhuisen D.J., Silke B. et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence. Results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112(16):2426–35.Tu K., Mamdani M., Kopp A., Lee D. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Am J Cardiol 2005;95(2):283–6.Tu K., Mamdani M., Kopp A., Lee D. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Am J Cardiol 2005;95(2):283–6.

The authors declare that there are no conflicts of interest present.